Overview

First Line Ovarian Cancer Treatment - Cohort Study

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
0
Participant gender:
Female
Summary
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Patients aged 18 years and over,

- Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will
receive bevacizumab (Avastin ®) in first-line therapy

- Patients should be informed of the study orally and should not have any objection
their data to be processed.

Exclusion Criteria:

- Patient participation in a clinical trial

- Patient non-affiliated to a social security scheme.